Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery

Nanjing Medical University

Status and phase: Enrolling; Phase 2

Conditions: Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) At High Risk of Recurrence After Curative Resection or Ablation; Hepatocellular Carcinoma (HCC)

Treatments: Drug: Postoperative adjuvant lenvatinib; Other: Supportive care measures

Study type: Interventional

Funder types: Other

Identifiers

NCT06762782

2024-SR-708

Details and patient eligibility

About

This study is a prospective, randomized, controlled, open, phase II, multicenter clinical study, which aims to evaluate the efficacy and safety of lenvatinib for adjuvant treatment of high-risk recurrent liver cancer after radical surgery.

This study is divided into 3 stages: screening period (screening period 28 days), treatment period (up to 12 months, or until any of the following occurs, whichever occurs first: ① The subject has an intolerable toxic reaction and is still not relieved after dose adjustment; ② The subject's first imaging confirmed disease recurrence or withdrew from the study for other reasons), and follow-up period (12 months after the end of treatment).

Dosage regimen:

Eligible subjects were randomly assigned to the experimental group or the control group in a 2:1 ratio, with surgical method (radical surgery vs ablation) as the stratification factor. The experimental group received lenvatinib treatment, and the control group received best supportive care

Enrollment: 276 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Certainly, here is the translation of the provided text into English:

  1. Age between 18 to 80 years old, gender not limited;
  2. Received radical treatment surgery for liver cancer within 4 to 8 weeks prior to enrollment, and meet the following criteria: (1) Intraoperative judgment criteria: ① No gross tumor thrombus in the hepatic vein, portal vein, bile duct, and inferior vena cava; ② No invasion of adjacent organs, no hepatic hilum lymph nodes or distant metastasis; ③ The liver resection margin is ≥1cm from the tumor border; if the margin is less than 1cm, the histological examination of the resected liver surface shows no residual tumor cells, i.e., negative resection margin. (2) Postoperative judgment criteria: ① Ultrasound, computed tomography(CT), magnetic resonance imaging(MRI) examinations (at least two of these) are performed within 1 to 2 months after surgery, with no residual or recurrent tumor lesions in radical resection cases, and no active tumor lesions in radical ablation cases; ② If serum alpha-fetoprotein(AFP), des-gamma-carboxy prothrombin(DCP), and a combination of 7 Micro ribonucleic acid(microRNAs) and other tumor markers were elevated before surgery, then quantitative measurement of tumor markers is required 8 weeks after surgery, and their levels drop to the normal range; if serum alpha-fetoprotein(AFP) does not return to normal within 8 weeks after surgery , will not be included.
  3. Postoperative pathological examination confirms hepatocellular carcinoma(HCC), and all tumor nodules are completely removed with negative resection margins.
  4. Imaging examinations ≥4 weeks after surgery confirm no recurrence or metastasis.
  5. Expected survival >3 months;
  6. hepatitis B virus(HBV) deoxyribonucleic acid(DNA) <10^4 copies/ml (2000 IU/ml), if hepatitis B virus(HBV) deoxyribonucleic acid(DNA) ≥10^4 copies/ml, antiviral treatment should be initiated first until hepatitis B virus(HBV) deoxyribonucleic acid(DNA) is reduced to below 10^4 copies/ml before entering the study, and continue to take antiviral medication and monitor liver function and hepatitis B virus(HBV) load.
  7. At least one of the following high recurrence risk factors exists:
  <!-- -->
  1. Tumor diameter >5cm
  2. Multiple lesions (>3)
  3. Pathology indicates MVI positivity
  4. Edmondson III-IV grade
  5. Persistently abnormal alpha-fetoprotein 8. No history of other tumors, and no antitumor treatment before surgery; 9. Eastern Cooperative Oncology Group(ECOG) score: 0-1. 10. Major organ functions are normal, i.e., meeting the following criteria:

Hematology examination (within 14 days before screening, without blood transfusion or use of granulocyte colony stimulating factor(G-CSF)):

1. Hemoglobin ≥90 g/L;

2. Absolute neutrophil count (ANC) ≥1.5×10^9/L;

3. Platelet count ≥75×10^9/L;

   Biochemical examination (within 14 days before screening, without the use of albumin):

4. Albumin ≥28 g/L;

5. Total bilirubin ≤1.5×upper limit of normal (ULN);

6. Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) ≤3×ULN;

7. Creatinine ≤1.5×ULN;

   Coagulation function:

8. International normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN;

9. Activated partial thromboplastin time (APTT) ≤1.5×ULN. 11.Patients with reproductive capacity, both male and female, must use reliable contraceptive measures during the study medication use and for 60 days after the last dose.

Exclusion criteria

• Here is the translation of the provided text into English:

  1. Pathologically diagnosed as a mixed type of hepatocellular carcinoma-intrahepatic cholangiocarcinoma (HCC-ICC).
  2. Positive surgical margins or tumor rupture.
  3. Reoperation for recurrent liver cancer.
  4. History of other malignancies within 5 years, unless the patient has undergone potentially curative treatment and has no evidence of the disease for 5 years, except for patients who have successfully undergone resection surgery for skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ, or other carcinoma in situ (the 5-year requirement does not apply).
  5. Past or current congenital or acquired immunodeficiency diseases.
  6. Patients who have undergone allogeneic transplantation.
  7. Insufficient biopsy and/or surgical samples are unavailable.
  8. Pregnant and breastfeeding patients.
  9. Received targeted drug therapy such as sorafenib, lenvatinib, regorafenib, or immunomodulatory therapy such as anti-PD-1, anti-PD-L1, anti-CTLA-4 before surgery.
  10. Unable to provide informed consent (due to language, intellectual capacity, etc.).
  11. Active bleeding or coagulation abnormalities, with a tendency to bleed or currently undergoing thrombolytic, anticoagulant, or antiplatelet therapy.
  12. History of gastrointestinal bleeding within the past 4 weeks or a clear tendency towards gastrointestinal bleeding (e.g., known active local ulcer lesions, fecal occult blood ++ or more, if persistent fecal occult blood +, gastroscopy should be performed), or other conditions that may cause gastrointestinal bleeding as determined by the investigator (e.g., severe gastric fundus/esophageal varices).
  13. Significant clinically meaningful cardiovascular diseases, including but not limited to acute myocardial infarction, severe/unstable angina, or coronary artery bypass grafting within the past 6 months, congestive heart failure (New York Heart Association NYHA class >2), arrhythmias that are poorly controlled or require pacemaker treatment, uncontrolled hypertension with medication (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg).
  14. Allergy to chemotherapy drugs or contraindications to surgery.
  15. History of thrombosis or thromboembolic events within the past 6 months, such as stroke and/or transient ischemic attack, deep vein thrombosis, pulmonary embolism, etc.
  16. History of gastrointestinal perforation, abdominal fistula, or intra-abdominal abscess within the past 6 months.
  17. Not yet recovered from surgery, such as having unhealed incisions or severe postoperative complications.
  18. History of alcohol, psychotropic drugs, or other drug abuse within the past 6 months.
  19. Presence of other serious diseases that the investigator deems unsuitable for participation in this study;
  20. Currently participating in other therapeutic/interventional clinical trials.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

276 participants in 2 patient groups

Treatment group

Experimental group

Description:

According to the instructions, lenvatinib 8mg (weight ≤ 60Kg) or 12mg (weight ≥ 60Kg) was given orally once a day, and active monitoring was performed.

Treatment:

Drug: Postoperative adjuvant lenvatinib

Control group

Other group

Description:

After surgery, the best supportive care was given, and active monitoring was performed.

Treatment:

Other: Supportive care measures